# Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

> **NCT04499924** · PHASE2,PHASE3 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 17 (actual)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** tucatinib
- **DRUG:** trastuzumab
- **DRUG:** ramucirumab
- **DRUG:** paclitaxel
- **OTHER:** tucatinib placebo
- **OTHER:** trastuzumab placebo

## Key facts

- **NCT ID:** NCT04499924
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-22
- **Primary completion:** 2024-04-17
- **Final completion:** 2024-04-17
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04499924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04499924, "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04499924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*